# Veradermics, Inc: overview

MANE · NYSE · CIK 1827635 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mane.md) · [Financials](/companies/mane/financials.md) · [Filings](/companies/mane/filings.md) · [Insiders](/companies/mane/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(19.79)](/filings/0001827635-26-000019.md) | [(24.19)](/filings/0001827635-26-000030.md) | [(1.32)](/filings/0001827635-26-000019.md) | [(0.58)](/filings/0001827635-26-000030.md) |
| Free cash flow | $m | [(13.3)](/filings/0001827635-26-000019.md) | [(15.6) d](/filings/0001827635-26-000030.md) | [(21.2)](/filings/0001827635-26-000019.md) | [(14.5) d](/filings/0001827635-26-000030.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $m | not reported | not reported |
| Gross margin | % | not reported | not reported |
| Operating margin | % | not reported | not reported |
| Net margin | % | not reported | not reported |
| Diluted EPS | $ per share | [(37.05)](/filings/0001827635-26-000013.md) | [(111.91)](/filings/0001827635-26-000013.md) |
| Free cash flow | $m | [(23.7)](/filings/0001827635-26-000013.md) | [(71.6)](/filings/0001827635-26-000013.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mane/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $512.5m | 4,168,970 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $394.0m | 3,204,981 |  | Added +1,412,072 |
| [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $295.3m | 2,401,868 |  | Unchanged |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $245.9m | 2,000,000 |  | Added +1,500,000 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $230.9m | 1,877,775 |  | Added +52,103 |
| [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $203.5m | 1,655,374 |  | Added +150,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $195.9m | 1,593,791 |  | Added +1,311,180 |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $192.0m | 1,561,494 |  | Reduced −129,061 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $144.2m | 1,165,584 |  | Added +189,418 |
| [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $134.8m | 1,096,642 |  | Added +41,982 |

## Recent filings

[All 96 filings](/companies/mane/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 13:06 ET | [8-K](/filings/0001827635-26-000036.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001827635-26-000036 |
| 2026-08-21 | 22:32 ET | [SCHEDULE 13D/A](/filings/0000899140-26-000948.md) | Ownership report, active investor, amended | 0000899140-26-000948 |
| 2026-08-14 | 00:00 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000686.md) | Ownership report, active investor, amended | 0001072613-26-000686 |
| 2026-08-11 | 20:38 ET | [10-Q](/filings/0001827635-26-000030.md) | Quarterly report, period 2026-06-30 | 0001827635-26-000030 |
| 2026-08-11 | 12:15 ET | [8-K](/filings/0001827635-26-000028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001827635-26-000028 |
| 2026-08-07 | 21:08 ET | [S-1](/filings/0001628280-26-054921.md) | Registration statement | 0001628280-26-054921 |
| 2026-07-15 | 12:54 ET | [8-K](/filings/0001827635-26-000023.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001827635-26-000023 |
| 2026-05-12 | 21:06 ET | [10-Q](/filings/0001827635-26-000019.md) | Quarterly report, period 2026-03-31 | 0001827635-26-000019 |
| 2026-05-12 | 12:32 ET | [8-K](/filings/0001827635-26-000016.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001827635-26-000016 |
| 2026-05-05 | 01:39 ET | [SCHEDULE 13D/A](/filings/0000899140-26-000416.md) | Ownership report, active investor, amended | 0000899140-26-000416 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001827635-26-000013.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1827635
- Tickers: MANE
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.